The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MS...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Bennouna
Citation Annals of Oncology (2016) 27 (2): 1-3. 10.1093/annonc/mdw237
Authors J. Bennouna1, P.-. Etienne2, E. Bogart3, M.-. Galais4, M. Benabdelghani5, E. Francois6, P. Michel7, L. Dahan8, J.-. Metges9, F. Ghiringhelli10, T. Conroy11, N. Kotecki3, L. Bedenne12, F. El Hajbi3, E. Samalin13, G. Piessen14, S. Delaine-Clisant3, N. Penel3, C. Mariette14, A. Adenis3
  • 1Institut de cancérologie de la Loire, Nantes, France, /
  • 2Hôpital Privé des Côtes d'Armor, Plérin, France, /
  • 3Centre Oscar Lambret, Lille, France, /
  • 4Centre François Baclesse, Caen, France, /
  • 5Centre Paul Strauss, Strasbourg, France, /
  • 6Centre Antoine Lacassagne, Nice, France, /
  • 7University Hospital Pierre Nicolle, Rouen, France, /
  • 8University Hospital La Timone, Marseille, France, /
  • 9University Hospital Morvan, Brest, France, /
  • 10Centre Georges-François Leclerc, Dijon, France, /
  • 11Institut de cancérologie de Lorraine, Nancy, France, /
  • 12University Hospital Le Bocage, Dijon, France, /
  • 13Institut du cancer de Montpellier, Montpellier, France, /
  • 14University Hospital Claude Huriez, Lille, France, /

Abstract

There is no evidence to support the use of CT in MSEC patients (pts). To better estimate the benefit of CT in this setting, we designed a discontinuation phase 2 trial in pts free from progression after 6 weeks of CT.